skip to content


Issue No. 8 | March 8, 2013

News and Features

March 10 Observance Highlights the Impact of HIV/AIDS on Women and Girls

Mark your calendar for March 10, the eighth annual observance of National Women and Girls HIV/AIDS Awareness Day. The day serves to highlight the burden of HIV/AIDS on women and girls, which is reflected in the following statistics from CDC: 

  • One in 139 women in the United States will receive a diagnosis of HIV infection at some point in her lifetime.  
  • In 2009, there were an estimated 11,200 new HIV infections among women in the United States. That year, women represented 51% of the U.S. population and 23% of those newly infected with HIV.

To learn more, visit our National Women and Girls HIV/AIDS Awareness Day page [en español].

Recent News from NIH and FDA

NIH-sponsored researchers announced the following news at the Conference on Retroviruses and Opportunistic Infections (CROI) this week:

  • March 4, 2013: Daily-Use HIV Prevention Approaches Prove Ineffective Among Women in NIH Study

    “Three antiretroviral-based strategies intended to prevent HIV infection among women did not prove effective in a major clinical trial in Africa.”

    Read the NIH press release.
  • March 3, 2013: Toddler ‘Functionally Cured’ of HIV Infection, NIH-Supported Investigators Report

    “A two-year-old child born with HIV infection and treated with antiretroviral drugs beginning in the first days of life no longer has detectable levels of virus using conventional testing despite not taking HIV medication for 10 months … .”

    Read the NIAID press release.

FDA recently announced the following labeling updates: 

  • March 1, 2013: Intelence (Etravirine) Labeling Updates
    “FDA approved changes to the Intelence (etravirine) label to include revisions to the Warnings and Precautions, Adverse Reactions, and Postmarketing Experience sections … .”

    Read the FDA announcement and view the AIDSinfo patient drug summary for etravirine.
  • March 1, 2013: Prezista (Darunavir) Label Change - Drug Interaction Information

    “The FDA recently approved changes to the Prezista (darunavir) label to reflect drug interaction information with artemether/lumefantrine.”

    Read the FDA announcement and view the AIDSinfo patient drug summary for darunavir.

CDC Releases 2011 HIV Surveillance Report

The Centers for Disease Control and Prevention (CDC) recently released the HIV Surveillance Report, 2011, Vol. 23. The annual report summarizes information about diagnosed HIV infection in the United States and dependent areas. CDC’s public health partners in other federal agencies, health departments, nonprofit organizations, academic institutions, and the general public use the HIV surveillance data in the report to help focus prevention efforts, plan services, allocate resources, develop policy, and monitor trends in HIV infection.